http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PE-20190503-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e8ab16a9037ecb102a8cb8ae05cc8a8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4747 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-438 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4747 |
| filingDate | 2017-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25d2576cd917fac268d5cf46f79f693c |
| publicationDate | 2019-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PE-20190503-A1 |
| titleOfInvention | NMDA ESPIRO-LACTAM RECEIVER MODULATORS AND USE OF THE SAME |
| abstract | It refers to a compound represented by the exposed formula, or a pharmaceutically acceptable salt and / or a stereoisomer thereof, characterized in that: X and Y are NR1 or CR2R2 (one of these is NR1); R1 is selected from H, C1-C6 alkyl, among others; q is 0 or 1; r is 1 or 2; R2 is independently selected from H, halogen, among others; R3 is selected from H, phenyl, among others; R5 is independently selected from H, C1-C6 alkyl, among others; R6 is 1 or 2 substituents for each available ring carbon (selected from halogen, C1-C6 alkyl, among others); R7 is independently selected from H, halogen, among others; and R9 is independently selected from H, halogen, among others; and a pharmaceutical formulation or composition comprising the compound of the invention (it can be its racemic mixture) together with a pharmaceutically acceptable excipient (according to its route of administration. It also refers to methods of preparation and treatment (for this they can also be used combination therapies with one or more other active agents.) The present invention is useful for the treatment of conditions such as depression and related disorders by modulating the activity of the N-methyl-d-aspartate receptor (NMDA). |
| priorityDate | 2016-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.